• Conference Proceeding

OUTCOME ASSESSMENTS OF PRIMARY ENDPOINTS OF NEW DRUGS APPROVED BY THE FDA (2011-2015) [MEETING ABSTRACT PHP101]

Citation

Gnanasakthy, A., & DeMuro, C. (2016). OUTCOME ASSESSMENTS OF PRIMARY ENDPOINTS OF NEW DRUGS APPROVED BY THE FDA (2011-2015) [MEETING ABSTRACT PHP101]. Value in Health (ISPOR 21st Annual International Meeting), 19(3), A275.

Abstract

studies of recent FDA approvals. PROs were key to assess treatment benefit in diseases such as those related to genitourinary, digestive and musculoskeletal systems as per respective regulatory guidance.